Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.
Market Cap
6.411T
Market Weight
11.08%
Industries
11
Companies
1202
Healthcare S&P 500 ^GSPC
Loading Chart for Healthcare
DELL

Day Return

Sector
0.03%
S&P 500
1.02%

YTD Return

Sector
1.28%
S&P 500
6.92%

1-Year Return

Sector
3.32%
S&P 500
25.26%

3-Year Return

Sector
2.47%
S&P 500
22.00%

5-Year Return

Sector
61.84%
S&P 500
73.29%

Note: Sector performance is calculated based on the previous closing price of all sector constituents

Industries in This Sector

Select an Industry for a Visual Breakdown

IndustryMarket WeightDay ReturnYTD Return
All Industries 100% 0.03% 1.28%
Drug Manufacturers - General 33.70% -0.03% 5.69%
Healthcare Plans 13.55% 0.09% -4.38%
Medical Devices 13.04% 0.08% 3.93%
Diagnostics & Research 11.52% -0.02% 2.11%
Biotechnology 11.00% 0.03% -9.21%
Medical Instruments & Supplies 6.72% -0.05% 2.83%
Medical Care Facilities 2.87% -0.04% 7.19%
Drug Manufacturers - Specialty & Generic 2.73% 0.17% -7.70%
Medical Distribution 2.48% 0.04% 11.86%
Health Information Services 2.16% 0.68% 7.65%
Pharmaceutical Retailers 0.24% 0.02% -31.95%

Note: Percentage % data on heatmap indicates Day Return

All Industries

Largest Companies in This Sector

Name
Last Price
1Y Target Est.
Market Weight
Market Cap
Day Change %
YTD Return
Avg. Analyst Rating
733.51 826.94 11.03% 697.396B +1.19% +25.83%
Buy
495.35 566.61 7.21% 455.762B +0.30% -5.91%
Buy
146.14 173.75 5.57% 352.165B -0.46% -6.76%
Buy
131.20 138.98 5.26% 332.334B +0.37% +20.34%
Buy
159.62 184.70 4.49% 283.491B -4.58% +3.00%
Buy
573.60 616.78 3.46% 218.951B +0.33% +8.07%
Buy
107.53 126.69 2.95% 186.584B +0.63% -2.31%
Buy
246.58 270.66 2.89% 182.639B +0.32% +6.59%
Buy
269.98 306.20 2.32% 146.762B +0.22% -6.26%
Buy
25.40 31.10 2.28% 143.829B +0.55% -11.77%
Buy

Investing in the Healthcare Sector

Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds

ETF Opportunities

Name
Last Price
Net Assets
Expense Ratio
YTD Return
139.96 41.319B 0.09% +2.63%
255.32 21.195B 0.10% +1.84%
126.49 7.632B 0.45% -6.89%
83.49 7.551B 0.35% -6.50%
55.53 5.76B 0.40% +2.89%

Mutual Fund Opportunities

Name
Last Price
Net Assets
Expense Ratio
YTD Return
206.36 47.432B 0.29% -1.32%
87.01 47.432B 0.29% -1.32%
127.79 21.195B 0.10% +1.89%
89.79 15.399B 0.80% +2.15%
92.74 15.399B 0.80% +5.24%

Healthcare Research

Discover the Latest Analyst and Technical Research for This Sector

  • Analyst Report: Cronos Group Inc.

    Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.

    Rating
    Price Target
     
  • Analyst Report: Zoetis Inc.

    Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

    Rating
    Price Target
     
  • Analyst Report: Gilead Sciences, Inc.

    Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

    Rating
    Price Target
     
  • Analyst Report: Walgreens Boots Alliance Inc

    Walgreens Boots Alliance Inc. based in Deerfield, Illinois, is a holding company created in December 2014 when Walgreen completed its purchase of privately held Alliance Boots. The company generated $139 billion in FY23 sales. After divesting its healthcare distribution business WBA has presence in more than 9 countries. About 85% of revenue is from the United States. The company has over 14,000 stores under the Walgreen, Duane Reade and Boots names. WBA owns about 16% of Cencora. WBA's fiscal year ends on August 31. The company has reclassified its operations again. The new organization has a United States Retail Pharmacy unit, an International unit, and a U.S. Healthcare segment, which includes recent investments in VillageMD, CareCentrix and Shields Health Solutions.

    Rating
    Price Target
     

From the Community

Healthcare News